U-47700: Complete Toxicology, Overdose, Dependence, Withdrawal & Safety Monograph

U-47700: Complete Toxicology, Overdose, Dependence, Withdrawal & Safety Monograph

Emergency safety: U-47700 is a potent opioid. If someone is difficult or impossible to wake, has slow, shallow or stopped breathing, blue/gray lips, choking/gurgling while unresponsive, or collapses after an unknown pill or powder, call emergency services and give naloxone if available.

Quick answer

U-47700 is a potent non-fentanyl synthetic opioid and mu-opioid receptor agonist. It was developed by the Upjohn Company during opioid medicinal-chemistry research in the 1970s, never became an approved medicine, and decades later re-emerged in illicit markets after its structure and pharmacology were accessible in patents and scientific literature.

U-47700 became internationally notorious because it appeared:

• as powder sold directly as a “research chemical”;
• in counterfeit prescription opioid tablets;
• in counterfeit alprazolam/Xanax-type tablets;
• in polydrug opioid mixtures;
• in the street mixture called “gray death.”

Its clinical picture is classic opioid toxicity:

• reduced consciousness;
• slowed breathing;
• pinpoint pupils;
• pulmonary edema in severe/fatal cases;
• respiratory arrest and death.

Unlike many very new RC opioids, U-47700 has a meaningful human literature and a long enough history to show how an abandoned medicinal-chemistry compound can become a public-health threat when diverted into unregulated markets.

---

Evidence at a glance

---

Identity

Canonical name: U-47700
Class: non-fentanyl synthetic opioid / benzamide opioid
Primary pharmacologic target: mu-opioid receptor
Approved medical use: none
Historical developer: Upjohn Company

U-47700 is chemically distinct from fentanyl and the nitazenes.

That matters because the phrase “synthetic opioid” describes pharmacology, not one chemical family.

---

History: from pharmaceutical research to the illicit market

U-47700 originated in Upjohn's opioid medicinal-chemistry work in the 1970s.

Researchers were exploring substituted cyclohexyl benzamides with strong MOR activity.

U-47700 showed potent analgesic effects in preclinical models but was never approved or marketed as a therapeutic drug.

For decades it was largely a literature/patent compound.

Re-emergence

By the mid-2010s, U-47700 began appearing through internet “research chemical” markets.

Its rise illustrates a pattern now repeated across NPS markets:

1. an old medicinal-chemistry scaffold exists in the literature;
2. clandestine manufacturers reproduce it;
3. it enters online/retail drug markets;
4. poisonings and deaths appear before routine testing catches up.

---

Pharmacology

U-47700 is a potent mu-opioid receptor agonist.

MOR activation can produce:

• analgesia;
• euphoria;
• sedation;
• miosis;
• respiratory depression;
• constipation;
• tolerance;
• physical dependence.

Older preclinical literature described U-47700 as more potent than morphine in animal analgesia tests.

That historical animal ratio should not be converted into a human dose ratio.

---

Human clinical evidence

A 2017 clinical review identified 16 human patients from the then-available literature. PMID 28911989

Survivors commonly presented with:

• decreased mental status;
• decreased respiratory rate;
• opioid-type toxidrome;
• tachycardia.

Fatal cases commonly involved pulmonary edema.

No controlled clinical safety trial established a therapeutic or safe recreational exposure.

---

Fatality evidence

U-47700 has been involved in numerous deaths internationally.

Importantly, some fatalities involved multiple drugs, while others provide stronger single-drug evidence.

A Kansas case report described a death attributed to U-47700 alone, demonstrating that co-occurring fentanyl is not necessary for lethal opioid toxicity. PMID 29040568

Later forensic literature continued documenting U-47700 in polydrug deaths. PMID 38831139

---

Counterfeit pills

Counterfeit pharmaceuticals are one of the most important U-47700 lessons.

DEA documented counterfeit tablets presented as prescription opioids that actually contained U-47700.

A published case also described an unintentional U-47700 overdose after counterfeit Xanax use. PMID 30789871

This means a person can encounter U-47700 while seeking:

• oxycodone;
• alprazolam;
• another familiar prescription drug.

A pill imprint is not chemical identification outside the legitimate pharmacy supply.

---

“Gray death”

U-47700 became associated with a dangerous street mixture often called gray death.

Gray death is not one standardized formula.

Reports have described combinations involving substances such as:

• heroin;
• fentanyl or fentanyl analogues;
• U-47700;
• other opioids.

The term should therefore be understood as a variable polysubstance market label, not a specific chemical product.

---

What overdose looks like

Possible U-47700 overdose includes:

• extreme sleepiness;
• inability to awaken;
• slow or shallow breathing;
• apnea;
• blue/gray lips;
• pinpoint pupils;
• collapse;
• pulmonary edema;
• cardiac arrest.

Respiratory depression is the central life-threatening mechanism.

---

Naloxone

Naloxone is the appropriate opioid antagonist when U-47700 poisoning is suspected.

Published clinical experience supports successful reversal of U-47700 opioid toxicity. PMID 32284916

Important limitation

Naloxone does not identify the drug.

It can reverse the opioid component of an unknown overdose while:

• benzodiazepines;
• alcohol;
• xylazine;
• other sedatives

remain active.

Emergency observation is therefore still necessary.

---

Drug testing: why routine screens can fail

The 2017 clinical review specifically noted that standard immunoassays failed to identify U-47700.

Confirmation required chromatographic and spectral techniques. PMID 28911989

A negative routine opioid screen should therefore not override a convincing opioid toxidrome.

---

Definitive analytical detection

Published methods have used:

• LC-MS/MS;
• LC-HRMS;
• GC-MS;
• metabolite libraries.

Advanced methods are especially important because novel synthetic opioids can occur at low concentrations and outside normal screening panels.

---

Metabolism

Human-liver-microsome and authentic-urine research has identified U-47700 metabolites useful for toxicology.

A forensic case report emphasized that extensive metabolism can make metabolite identification crucial when the parent drug is difficult to detect. PMID 30443678

This is a recurring lesson across NPS toxicology:

Testing only for the parent compound can miss an exposure that metabolite-aware analysis would identify.

---

Polysubstance risk

U-47700 has often appeared with:

• fentanyl/fentanyl analogues;
• heroin;
• benzodiazepines;
• other novel opioids.

Multiple opioid agonists can produce severe respiratory depression even when no single drug concentration appears extraordinary.

This is one reason blood concentrations from death cases cannot be converted into a personal threshold.

---

Tolerance

Repeated MOR agonism can produce opioid tolerance.

A person may require more exposure to achieve the same subjective effect while remaining vulnerable to:

• respiratory depression;
• polysubstance toxicity;
• product-strength variability.

After a period of abstinence, tolerance can decline.

Returning to previous exposure patterns can then sharply increase overdose risk.

---

Physical dependence

Direct prospective U-47700 dependence cohorts are limited.

However, U-47700 is a potent MOR agonist, and repeated opioid agonism can produce physical dependence.

Dependence means the body has adapted so that withdrawal appears when exposure falls.

It is not identical to addiction.

---

Withdrawal

U-47700-specific controlled withdrawal timelines are not established.

Expected opioid withdrawal can include:

• restlessness;
• anxiety;
• insomnia;
• sweating/chills;
• runny nose/tearing;
• yawning;
• muscle aches;
• abdominal cramps;
• nausea/vomiting;
• diarrhea;
• craving.

There is no validated U-47700 home-taper protocol.

A person dependent on a counterfeit or variable product may not even know the true daily exposure.

---

Addiction / opioid use disorder

Signs of OUD can include:

• inability to cut down;
• craving;
• escalating use;
• continued use despite overdose;
• work/family problems;
• hazardous use;
• substantial time obtaining/using/recovering;
• tolerance;
• withdrawal.

A person can be physically dependent without meeting all OUD criteria.

---

Treatment and support

There is no medication specifically approved for “U-47700 addiction.”

Established opioid use disorder treatment applies.

Evidence-based medications include:

• buprenorphine;
• methadone;
• extended-release naltrexone in appropriate patients.

This page intentionally does not provide home induction or taper doses.

For U.S. treatment resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

---

Forensic interpretation

A U-47700-positive postmortem result must be interpreted with:

• co-drugs;
• tolerance;
• scene evidence;
• medical history;
• concentration;
• specimen type;
• metabolism;
• timing.

Some deaths involve U-47700 alone.

Many others are mixed intoxications.

Both can be true.

---

Legal and regulatory history

United States

DEA temporarily placed U-47700 in Schedule I effective November 14, 2016 after finding an imminent hazard to public safety. PMID 27905978

DEA permanently maintained U-47700 in Schedule I in 2018. PMID 30016012

International

WHO recommended Schedule I control in 2016.

The UN Commission on Narcotic Drugs placed U-47700 in Schedule I of the 1961 Single Convention in March 2017, and the decision entered into force in April 2017. UNODC

---

Special populations

Direct U-47700 studies are absent for:

• pregnancy;
• breastfeeding;
• adolescents;
• older adults;
• chronic lung disease;
• sleep apnea;
• liver/kidney disease.

The lack of data is not evidence of safety.

Particular concern applies to:

• opioid-naive people;
• people using counterfeit pills;
• people combining benzodiazepines/alcohol;
• people recently abstinent from opioids;
• people using alone.

---

Myths and misconceptions

“U-47700 is just fentanyl with a different name.”

False. It is a different chemical class.

“A Xanax-looking tablet cannot contain an opioid.”

False. Counterfeit alprazolam exposure containing U-47700 has been documented.

“A negative hospital opioid screen rules it out.”

False.

“Gray death is one consistent drug.”

False. It is a variable mixture/market label.

“A lethal blood concentration tells you the lethal dose.”

No. Blood concentration and ingested amount are not interchangeable, especially postmortem.

“Because U-47700 is older, it is well studied in humans.”

False. The molecule is old; controlled human safety data are not.

---

What we know vs what remains unknown

Established

• U-47700 is a potent MOR agonist;
• it can cause classic opioid respiratory depression;
• fatal intoxications are documented;
• counterfeit-pill exposure occurs;
• routine immunoassays can miss it;
• naloxone is appropriate;
• U.S. and international Schedule I control is established.

Strongly plausible / class-supported

• tolerance;
• physical dependence;
• opioid withdrawal;
• loss-of-tolerance overdose risk;
• increased danger with other depressants.

Not established

• safe recreational dose;
• universal lethal concentration;
• controlled human PK;
• U-47700-specific withdrawal timeline;
• home taper protocol;
• long-term human safety;
• pregnancy safety.

---

Bottom line

U-47700 is one of the clearest historical examples of how old medicinal chemistry can become a new overdose problem.

Its story combines:

• a potent abandoned opioid scaffold;
• internet research-chemical sales;
• counterfeit pills;
• unintentional exposure;
• missed routine drug screens;
• polysubstance mixtures;
• fatal respiratory depression.

The central harm-reduction lesson remains current even though newer opioids now dominate headlines:

The name or appearance of an illicit pill does not establish its chemistry, and a negative routine opioid screen does not rule out a potent synthetic opioid.

Related evidence

• Designer synthetic opioids beyond nitazenes
• Nitazene opioids masterclass monograph
• Brorphine
• 2-Methyl-AP-237
• Substance Use, Dependence & Harm Reduction hub